Draupnir Bio Secures €12 Million Seed Funding to Pioneer Extracellular Protein Degradation – Startup Dope
Summary
Copenhagen, Denmark July 22, 2024 Draupnir Bio, a Danish biotechnology company, has closed a 12 million seed funding round. Our unique technology platform holds immense potential to revolutionize the field of TPD and bring new hope to patients suffering from complex diseases.The seed funding round was led by MP Healthcare and EIFO, alongside existing investors Gilde Healthcare Partners, Inkef Capital, and Novo Holdings. The funds will be used to further develop Draupnir Bios preclinical pipeline of oral, small-molecule protein degraders. Small Molecule Design: Enables efficient delivery of the drugs throughout the body.Draupnir Bios groundbreaking technology has the potential to significantly impact the field of medicine. By unlocking the power of extracellular protein degradation, they aim to develop innovative therapies for a wider range of diseases.Draupnir Bio is a company to watch closely.